GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gene Biotherapeutics Inc (OTCPK:CRXM) » Definitions » Effective Interest Rate on Debt %

Gene Biotherapeutics (Gene Biotherapeutics) Effective Interest Rate on Debt % : 4.00% (As of Dec. 2020)


View and export this data going back to . Start your Free Trial

What is Gene Biotherapeutics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Gene Biotherapeutics's annualized positive value of Interest Expense for the quarter that ended in Dec. 2020 was $0.05 Mil. Gene Biotherapeutics's average total debt for the quarter that ended in Dec. 2020 was $1.30 Mil. Therefore, Gene Biotherapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2020 was 4.00%.


Gene Biotherapeutics Effective Interest Rate on Debt % Historical Data

The historical data trend for Gene Biotherapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gene Biotherapeutics Effective Interest Rate on Debt % Chart

Gene Biotherapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.33 1.75 3.48 4.02 4.79

Gene Biotherapeutics Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.28 5.47 5.26 4.08 4.00

Competitive Comparison of Gene Biotherapeutics's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Gene Biotherapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gene Biotherapeutics's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gene Biotherapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Gene Biotherapeutics's Effective Interest Rate on Debt % falls into.



Gene Biotherapeutics Effective Interest Rate on Debt % Calculation

Gene Biotherapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2020 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2019 )+Total Debt  (A: Dec. 2020 ))/ count )
=-1  *  -0.057/( (1.121+1.261)/ 2 )
=-1  *  -0.057/1.191
=4.79 %

where

Total Debt  (A: Dec. 2019 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.122 + 0.999
=1.121

Total Debt  (A: Dec. 2020 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.108 + 1.153
=1.261

Gene Biotherapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2020 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2020 )+Total Debt  (Q: Dec. 2020 ))/ count )
=-1  *  -0.052/( (1.336+1.261)/ 2 )
=-1  *  -0.052/1.2985
=4.00 %

where

Total Debt  (Q: Sep. 2020 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.127 + 1.209
=1.336

Total Debt  (Q: Dec. 2020 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.108 + 1.153
=1.261

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2020) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Gene Biotherapeutics  (OTCPK:CRXM) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Gene Biotherapeutics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Gene Biotherapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Gene Biotherapeutics (Gene Biotherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11230 Sorrento Valley Road, Suite 220, San Diego, CA, USA, 92121
Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.
Executives
Andrew M Leitch director 6615 CALLE PONTE BELLA, RANCHO SANTA FE CA 92091
Murray H Hutchison director C/O CADIZ INC., 550 SOUTH HOPE STREET, 2850, LOS ANGELES CA 90071
Dennis Mulroy officer: Chief Financial Officer
Ronald I Simon other: Former Director 485 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Robert N Weingarten director, officer: PRESIDENT and CFO 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367

Gene Biotherapeutics (Gene Biotherapeutics) Headlines